A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Sponsor

Allyx Therapeutics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05804383

Collaborator

Yale University (Other), National Institute on Aging (NIA) (NIH)

Enrollment

Locations

Arms

15.6

Anticipated Duration (Months)

Patients Per Site

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease

Condition or Disease	Intervention/Treatment	Phase
Alzheimer's Disease	Drug: BMS-984923 Drug: Placebo	Phase 1

Detailed Description

This double-blind placebo-controlled study will be completed in 2 stages. The first stage will evaluate 10-days of BID dosing in four ascending dose cohorts in healthy older adults and Stage 2 will examine BMS-984923 dosed BID for 28 days at two dose levels in comparison to Placebo in participants with early AD.

This research study will assess the safety and tolerability of multiple doses of BMS-984923 for the treatment of early Alzheimer's Disease (AD) and investigate the use of synaptic density, measured with positron emission tomography (PET), as an early marker of therapeutic response to treatments that target synapse restoration.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Masking Description:

Placebo capsules

Primary Purpose:

Basic Science

Official Title:

A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease

Anticipated Study Start Date :

Mar 28, 2023

Anticipated Primary Completion Date :

Jul 15, 2024

Anticipated Study Completion Date :

Jul 15, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 50 mg active BMS-984923 50 mg in healthy participants	Drug: BMS-984923 Capsules Other Names: Active
Placebo Comparator: 50 mg Placebo Placebo 50 mg in healthy participants	Drug: Placebo Capsules Other Names: Inactive
Experimental: 100 mg Active BMS-984923 100 mg in healthy participants	Drug: BMS-984923 Capsules Other Names: Active
Placebo Comparator: 100 mg Placebo Placebo 100 mg in healthy participants	Drug: Placebo Capsules Other Names: Inactive
Experimental: 150 mg Active BMS-984923 150 mg in healthy participants	Drug: BMS-984923 Capsules Other Names: Active
Placebo Comparator: 150 mg Placebo Placebo 150 mg in healthy participants	Drug: Placebo Capsules Other Names: Inactive
Experimental: 225 mg Active BMS-984923 225 mg in healthy participants	Drug: BMS-984923 Capsules Other Names: Active
Placebo Comparator: 225 mg Placebo Placebo 225 mg in healthy participants	Drug: Placebo Capsules Other Names: Inactive
Experimental: 150 mg Active-AD BMS-984923 150 mg	Drug: BMS-984923 Capsules Other Names: Active
Experimental: 225 mg Active-AD BMS-984923 225 mg	Drug: BMS-984923 Capsules Other Names: Active
Placebo Comparator: Placebo-AD Placebo matching	Drug: Placebo Capsules Other Names: Inactive

Outcome Measures

Primary Outcome Measures

Stage 1 and Stage 2 Incidence of treatment-emergent adverse events (TEAEs) [Up to 10 days after last dose]
Stage 1 and Stage 2 Incidence of clinically significant lab abnormalities [Up to 10 days after last dose]
Stage 1 Incidence of clinically significant changes in safety assessments [Up to 10 days after last dose]
Vital signs, physical exam, electrocardiogram [ECG], Neuropsychiatric Inventory-Questionnaire [NPI Q], Geriatric Depression Scale [GDS], Glasgow Coma Scale [GCS], Montreal Cognitive Assessment [MOCA])
Stage 2 Incidence of clinically significant changes in safety assessments [Up to 10 days after last dose]
Vital signs, physical exam, ECG, NPI Q, GDS, MOCA, and Functional Assessment Questionnaire [FAQ])

Secondary Outcome Measures

Stage 1 and Stage 2 Trough plasma drug concentration at steady state [Up to 10 days after last dose]
Stage 1 and Stage 2 Area under the curve for the first 24 hours of dosing (AUC24h) and at steady state as determined by PK modeling [Up to 10 days after last dose]
Stage 2 Change from baseline in synaptic density PET [Up to 24 hours after last dose]
Stage 2 Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale 14 (ADAS-cog) score [Up to 7 days after the last dose]

Eligibility Criteria

Criteria

Ages Eligible for Study:

50 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria Stage 1:

Men or women between the ages of 50 and 80 years, inclusive
No history of cognitive impairment
Capable of providing written informed consent and willing to comply with all study requirements and procedures
Participant is not pregnant, lactating, or of childbearing potential
Non-childbearing potential for women is defined as postmenopausal (last natural menses greater than 24 months prior; menopausal status will be documented with serum follicle-stimulating hormone (FSH) or documentation of bilateral tubal ligation or hysterectomy
Male participants who are sexually active with a woman of childbearing potential must agree to use condoms during the trial and for 3 months after the last dose unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap.
Male participants must also agree not to donate sperm for 90 days after the last dose.
Montreal Cognitive Assessment (MOCA) >25

Exclusion Criteria Stage 1:

Body mass index (BMI) >38 kg/m2 or body weight <50 kg.
Any significant neurologic disease, such as AD, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
A current Diagnostic and Statistical Manual of Mental Disorders, Fifth revision (DSM

diagnosis of active major depression, schizophrenia or bipolar disorder. Participants with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.

Positive urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, opiates, tetrahydrocannabinol (THC), ethanol or cotinine (stable prescribed amphetamines or benzodiazepines for a non-exclusionary medical condition are permitted) or positive alcohol breathalyzer test
Current nicotine use or positive urine cotinine test.
History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the PI, may either put the participant at risk because of participation in the study, or influence the results, or the participant's ability to participate in the study.
Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g., small bowel disease, Crohn's disease, celiac disease, or liver disease.)
Seropositive for human immunodeficiency virus (HIV).
History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for hepatitis B surface antigen [HbsAg] or anti-hepatitis C [HCV] antibody).
Use of psychoactive medications (typical neuroleptics, narcotic analgesics, antiparkinsonian medications, systemic corticosteroids, or medications with significant central anticholinergic activity) within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial.
Use of medications with potential drug-drug interactions (see Appendix A for a list of these medications) within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial.
Use of anticoagulants within 30 days or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial.
Use of another investigational agent within 30 days or 5 half-lives (whichever is greater) prior to screening and for the duration of the trial.
Neutropenia defined as absolute neutrophils count of <1,500/microliter.
Thrombocytopenia defined as platelet count <100,000/microliter.
Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) >1.5 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN.
Geriatric Depression Scale (GDS) score of ≥5 and symptoms consistent with a current episode of major depression.

Inclusion Criteria Stage 2

Men or women between the ages of 50 and 80 years, inclusive, at the time of first dose of investigational product (IP).
Diagnosis of either amnestic mild cognitive impairment (aMCI) or mild dementia due to AD as defined by

Mild dementia due to AD
National Institute on Aging (NIA)-Alzheimer's Association core clinical criteria for dementia due to probable AD (McKhann 2011) and,
Mini Mental Status Exam (MMSE) score between 18 and 26 (inclusive)
Clinical Dementia Rating (CDR) global score of 0.5 or 1
aMCI due to AD
Subjective memory complaint preferably corroborated by an informant and,
Normal activities of daily living
CDR global score of 0.5
aMCI (Petersen 2004) as evidenced by abnormal memory function documented by scoring 1.5 SD below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25), and
8 for 16 or more years of education
4 for 8 15 years of education
2 for 0 7 years of education

Stable pharmacological treatment of any other chronic conditions for at least 4 weeks prior to baseline.
Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of AD as defined in Criteria 2 and without findings of significant exclusionary abnormalities (see Section 6.2.2, exclusion criteria, Number 4).
Study partner is available who has frequent contact with the participant (e.g., average of 10 hours per week or more), and can participate in all study partner assessments for the duration of the protocol.
Generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures as determined by the PI.
Must be able to complete all screening evaluations
Living at home or in the community (assisted living acceptable)
Ability to swallow study medication.
Modified Hachinski score ≤4
Capable of providing written informed consent and willing to comply with all study requirements and procedures
Participant is not pregnant, lactating, or of childbearing potential

Non-childbearing potential for women is defined as postmenopausal (last natural menses greater than 24 months prior; menopausal status will be documented with serum FSH or documentation of bilateral tubal ligation or hysterectomy
Male participants who are sexually active with a woman of childbearing potential must agree to use condoms during the trial and for 3 months after the last dose unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of IUD, male or female condom, diaphragm, sponge, and cervical cap.
Male participants must also agree not to donate sperm for 90 days after the last dose.

Exclusion Criteria Stage 2

Hospitalization or change of chronic concomitant medication within 4 weeks prior to baseline
BMI >38 kg/m2 or body weight <50 kg
Any contraindications for MRI studies, such as claustrophobia, the presence of metal (ferromagnetic) implants, metal fragments or foreign objects in the eyes, skin, or body or a cardiac pacemaker.
Living in a continuous care nursing facility
Screening MRI of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct >1 cm3, >3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, or space-occupying lesion (e.g., abscess or brain tumor such as meningioma)
Clinical or laboratory findings consistent with:

Other primary neurodegenerative disease or cognitive disorder (Lewy body disease, frontotemporal lobar disease, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, Parkinson's disease, amyotrophic lateral sclerosis, etc.)
Seizure disorder
Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 deficiency, other laboratory abnormalities, etc.)

A current DSM V diagnosis of active major depression, schizophrenia or bipolar disorder. Participants with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.
Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease that in the opinion of the PI, may either put the participant at risk because of participation in the study, or influence the results, or impair the participant's ability to participate in the study.
Disability that may prevent the participant from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc.)
Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g., small bowel disease, Crohn's disease, celiac disease, or liver disease.)
Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine) for 12 weeks prior to baseline
History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
Suspected or known allergy to any components of the study treatments
Any condition, which in the opinion of the investigator or Project Director (PD) makes the participant unsuitable for inclusion
Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study
Use of psychoactive medications (typical neuroleptics, narcotic analgesics, antiparkinsonian medications, systemic corticosteroids, or medications with significant central anticholinergic activity) within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial
Use of medications with potential drug-drug interactions (see Appendix A for a list of these medications) within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial.
Use of anticoagulants within 30 days or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the trial
Use of investigational amyloid lowering therapies within 2 months prior to study drug administration and for the duration of the trial.
Use of another investigational agent within 30 days or 5 half-lives (whichever is greater) prior to screening and for the duration of the trial
Neutropenia defined as absolute neutrophils count of <1,500/microliter
Thrombocytopenia defined as platelet count <100,000/microliter.
Clinically significant abnormalities in screening laboratories, including AST >1.5 times ULN; ALT >1.5 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN
GDS score of ≥5 and symptoms consistent with a current episode of major depression.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Yale University	New Haven	Connecticut	United States	06511
2	Spaulding Clinical Research	West Bend	Wisconsin	United States	53095

Sponsors and Collaborators

Allyx Therapeutics
Yale University
National Institute on Aging (NIA)

Investigators

Study Director: Adam Mecca, MD, PhD, Yale University
Principal Investigator: Stephanie Post, MD, Spaulding Clinical Research (Stage 1)
Principal Investigator: Adam Mecca, MD, PhD, Yale University (Stage 2)